Karyopharm Therapeutics | KPTI - Interest Expense On Debt


Karyopharm Therapeutics reported $12.62M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Abbott USD 68M 26M Mar/2026
Amgen USD 657M 4M Mar/2026
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
GlaxoSmithKline GBP 167M 21M Mar/2026
Incyte USD 569K 13K Mar/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 479M 67M Mar/2026
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novartis USD 343M 39M Mar/2026
Novartis USD 281M 8M Sep/2025
Pfizer USD 671M 40M Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Takeda JPY 43.65B 79.98B Mar/2026
Tectonic Therapeutic USD 246.58M 246.56M Mar/2026
TG Therapeutics USD 7.67M 1.13M Mar/2026
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Xencor USD 4.7M 2.65M Mar/2026